REG - N4 Pharma PLC - Result of AGM

N4 PharmaAnnouncement

23/04/2020 11:05

RNS Number : 6581K
  
N4 Pharma PLC
  
23 April 2020
  
 

23 April 2020
 
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
 
Result of Annual General Meeting
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. The results of the proxy voting for the AGM are set out below.
 







Resolution


Total votes For1


% of votes cast2


Total Votes Against


% of votes cast2


Total Votes Cast3


% of issued share capital


Votes Withheld4




1


To receive the annual report and audited accounts for the year ended 31 December 2019
 


30,624,816


100.00


-


0.00


30,625,416


30.18


200




2


To re-elect Nigel Theobald as a director of the Company
 


30,620,596


100.00


200


0.00


30,621,396


30.18


4,200




3


To re-elect David Templeton as a director of the Company
 


30,620,596


100.00


200


0.00


30,621,396


30.18


4,200




4


To re-appoint Saffery Champness LLP as auditor to the company and authorise the directors to determine their remuneration
 


30,624,796


100.00


200


0.00


30,625,596


30.18


200




5


To authorise the directors to allot shares
 


30,620,396


100.00


200


0.00


30,621,396


30.18


4,200




6


To disapply pre-emption rights*
 


30,618,996


100.00


200


0.00


30,620,596


30.18


5,000




7


To adopt new Articles of Association of the Company*
 


30,620,396


100.00


200


0.00


30,625,396


30.18


200



 
Notes:
 
*       Proposed as special resolutions
1.     Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution
2.     Percentage of votes cast excludes Votes Withheld
3.     Total Votes Cast do not include withheld votes
4.     Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution 
 
Enquiries:
 



N4 Pharma Plc
Nigel Theobald, CEO
 


 
Via Scott PR




Allenby Capital Limited
James Reeve/Asha Chotai 


Tel: +44(0)203 328 5656




Scott PR
Georgia Smith
 


Tel: +44(0)1477 539 539



 
About N4 Pharma
 
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
 
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
RAGGCGDSCUDDGGX